COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Burnet Institute will contribute its expertise in diagnostic development to a new AUD$5 million National Health and Medical Research Council (NHMRC) Centre for Research Excellence (CRE) to boost Australia’s response to infectious disease outbreaks.
The Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) brings together Australia’s leading experts in clinical, laboratory and public health research to address the need for a rapid and effective emergency response to infectious diseases.
Deputy Director of Burnet Institute and CEO of Burnet Institute’s spinoff Nanjing BioPoint Diagnostic Technologies, Associate Professor David Anderson will lead the work on development of serological lateral-flow POC tests for new pathogens and provide advice on commercialisation opportunities arising from the broader diagnostics work of the new CRE through close alignment with industry partners.
“Australia has well developed clinical and reference laboratory capacity for diagnosis of emerging infectious diseases which is strongly represented in the new CRE, but there is a critical need to develop new point-of-care (POC) diagnostic technologies,” Associate Professor Anderson said.
“We need new POC tests that can be deployed in remote areas of Australia and resource-poor settings throughout the Asia-Pacific region in order to deal with the threats of new pathogens.”
APPRISE will work with a newly established national network and with Commonwealth and State governments to create a sustainable research program to inform Australia’s emergency response to infectious diseases.
AUD$5 million from NHMRC